Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV000006718 | SCV000992809 | pathogenic | Dystonia 16 | 2017-12-31 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV000006718 | SCV001136091 | pathogenic | Dystonia 16 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001786327 | SCV002028673 | pathogenic | not provided | 2023-12-03 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate a damaging effect (PMID: 26231208); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 22194846, 26231208, 34758253, 18243799, 25737287, 29279192, 25142429, 26990861, 31216405, 33049316, 31589614, 33606314) |
Labcorp Genetics |
RCV000006718 | SCV002148103 | pathogenic | Dystonia 16 | 2024-10-29 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 222 of the PRKRA protein (p.Pro222Leu). This variant is present in population databases (rs121434410, gnomAD 0.02%). This missense change has been observed in individuals with autosomal recessive dystonia (PMID: 18243799, 25142429, 26990861). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 6346). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt PRKRA protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects PRKRA function (PMID: 26231208). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000006718 | SCV002809852 | pathogenic | Dystonia 16 | 2021-10-26 | criteria provided, single submitter | clinical testing | |
3billion | RCV000006718 | SCV003841619 | likely pathogenic | Dystonia 16 | 2023-10-06 | criteria provided, single submitter | clinical testing | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: <0.001%). Predicted Consequence/Location: Intron variant In silico tools predict the variant to alter splicing and produce an abnormal transcript [SpliceAI: 0.93 (>=0.2, moderate evidence for spliceogenicity)]. The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least one similarly affected unrelated individual (PMID: 36287101). The variant has been reported to be associated with LAMB3 related disorder (PMID: 36287101). Therefore, this variant is classified as Likely pathogenic according to the recommendation of ACMG/AMP guideline. |
Department of Pathology and Laboratory Medicine, |
RCV000006718 | SCV005916470 | pathogenic | Dystonia 16 | 2022-05-11 | criteria provided, single submitter | research | |
OMIM | RCV000006718 | SCV000026909 | pathogenic | Dystonia 16 | 2014-10-01 | no assertion criteria provided | literature only | |
Genomics England Pilot Project, |
RCV000006718 | SCV001760064 | pathogenic | Dystonia 16 | no assertion criteria provided | clinical testing | ||
Prevention |
RCV003914817 | SCV004730469 | pathogenic | PRKRA-related disorder | 2024-02-23 | no assertion criteria provided | clinical testing | The PRKRA c.665C>T variant is predicted to result in the amino acid substitution p.Pro222Leu. This variant was reported in the homozygous and compound heterozygous state in individuals with dystonia-parkinsonism and has been shown to segregate with disease in families (Camargos et al. 2008. PubMed ID: 18243799; Zech et al. 2014. PubMed ID: 25142429; Quadri et al. 2016. PubMed ID: 26990861; Dos Santos et al. 2017. PubMed ID: 29279192; Molloy et al. 2022. PubMed ID: 36186440). This variant is reported in 0.025% of alleles in individuals of Latino descent in gnomAD . In vitro experimental studies suggest this variant impacts protein function (Vaughn et al. 2015. PubMed ID: 26231208; Burnett et al. 2020. PubMed ID: 33049316). This variant is interpreted as pathogenic. |